

## COURSE FACULTY, IAS–USA STAFF, BOARD OF DIRECTORS, AND VIRAL HEPATITIS ADVISORY BOARD FINANCIAL RELATIONSHIPS WITH COMMERCIAL ENTITIES

In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, course faculty, IAS–USA Board members, Viral Hepatitis Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the previous 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity. The **ACCME defines a commercial interest** as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The **ACCME** does not consider providers of clinical service directly to patients to be **commercial interests** – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.” Below are the financial interests that faculty members of this course have had within the past 12 months as of the date listed. View the [Faculty Financial Disclosure Policy](#).

### LOS ANGELES, CALIFORNIA—MAY 6, 2019

Course Chairs	
<b>Constance A. Benson, MD</b> Professor of Medicine University of California San Diego La Jolla, California	<i>Dr Benson has served on advisory and data monitoring boards for GlaxoSmithKline/ViiV Healthcare and received research grants awarded to her institution from Gilead Sciences, Inc. Her spouse has served as a consultant to CytoDyn, Gilead Sciences, Inc, Pfizer, and Vir Biotechnology; has received grant support from Gilead Sciences, Inc; and holds stock or stock options in Antiva Biosciences and CytoDyn. (Updated 04/22/19)</i>
<b>Ronald T. Mitsuyasu, MD</b> Professor of Medicine David Geffen School of Medicine University of California Los Angeles Los Angeles, California	<i>Dr Mitsuyasu has received grants or research support from Calimmune, Janssen Therapeutics, and Sangamo BioSciences. (Updated 04/17/19)</i>
Speakers	
<b>Connie L. Celum, MD, MPH</b> Professor of Medicine and Global Health Adjunct Professor of Epidemiology University of Washington Seattle, Washington	<i>Dr Celum has participated in research trials that have received provision of medicines from Gilead Sciences, Inc. and has served as a scientific advisor to Merck &amp; Co, Inc. (Updated 04/15/19)</i>
<b>Peter Chin-Hong, MD</b> Professor of Medicine University of California San Francisco San Francisco, California	<i>Dr Chin-Hong has received research support from Karius. (Updated 12/07/18)</i>
<b>Eric S. Daar, MD</b> Professor of Medicine David Geffen School of Medicine University of California Los Angeles Los Angeles, California	<i>Dr Daar has received research support to his institution from Merck, ViiV Healthcare, and Gilead Sciences, Inc. He has served as a consultant and advisor, fees paid to his institution, for Gilead Sciences, Inc. (Updated 04/15/19)</i>
<b>Jeffrey D. Klausner, MD, MPH</b> Professor of Medicine and Public Health University of California Los Angeles David Geffen School of Medicine Los Angeles, California	<i>Dr Klausner has received royalties from McGraw-Hill Education and Walters Kluwer and received research support from or served as an advisor to Hologic, Cepheid, SpeedX, Click Diagnostics, and Shield Diagnostics. (Updated 04/09/19)</i>
<b>Marion G. Peters, MD</b> Professor of Medicine Chief of Hepatology Research University of California San Francisco San Francisco, California	<i>Dr Peters has served as an advisor to Abbott. Her spouse is employed by Hoffman-La Roche (Updated 04/17/19)</i>
IAS–USA CME Planner and Reviewer	
<b>Donna M. Jacobsen</b> Executive Director	<i>Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 04/29/19)</i>
IAS–USA Board of Directors	
The nonstaff members of the IAS–USA Board of Directors are not compensated for their roles in governing and overseeing the IAS–USA. Please see <a href="https://iasusa.org/about/ias-usa-board-of-directors/">https://iasusa.org/about/ias-usa-board-of-directors/</a> for information about board members and a link to up-to-date financial disclosure information.	
IAS–USA Viral Hepatitis Advisory Board	
The members of the IAS–USA Viral Hepatitis Advisory Board are not compensated for their roles in governing and overseeing the IAS–USA viral hepatitis educational efforts. Please see <a href="https://iasusa.org/activities/live-courses/hepatitis-c-virus-courses/viral-hepatitis-advisory-board/">https://iasusa.org/activities/live-courses/hepatitis-c-virus-courses/viral-hepatitis-advisory-board/</a> for information about the financial disclosures for the IAS–USA Viral Hepatitis Advisory Board.	